Accès membre

THE FILO PUBLICATIONS

Discover all the publications of the members of the FILO Group from 1981 to today.

PUBLICATIONS 2007-2013

Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Béral H, Ghia P, Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood. 2007 Jan 1;109(1):259-70.

Gary-Gouy H, Sainz-Perez A, Marteau JB, Marfaing-Koka A, Delic J, Merle-Beral H, Galanaud P, Dalloul A. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol. 2007 Oct 1;179(7):4335-44.

Planelles L, Castillo-Gutiérrez S, Medema JP, Morales-Luque A, Merle-Béral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica. 2007 Sep;92(9):1284-5.

Bras M, Yuste VJ, Roué G, Barbier S, Sancho P, Virely C, Rubio M, Baudet S, Esquerda JE, Merle-Béral H, Sarfati M, Susin SA. Drp1 mediates caspase-independent type III cell death in normal and leukemic cells. Mol Cell Biol. 2007 Oct;27(20):7073-88.

De Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008 Mar;140(6):635-43.

Duhamel M, Arrouss I, Merle-Béral H, Rebollo A. The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia. Blood. 2008 Mar 15;111(6):3225-8.

Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood. 2008 Feb 15;111(4):2388-91. Epub 2007 Dec 12.

Praz F, Le Page F, Vallat L, Davi F, Nguyen-Khac F, Maloum K, Delic J, Merle-Béral H. Absence of microsatellite instability in human chronic lymphocytic leukaemia B cells. Leukemia. 2008 Jan;22(1):186-9.

Su X, Della-Valle V, Delabesse E, Azgui Z, Berger R, Merle-Béral H, Bernard OA, Nguyen-Khac F. Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. Haematologica. 2008 Jul;93(7):1081-5.

Chapiro E, Radford-Weiss I, Bastard C, Luquet I, Lefebvre C, Callet-Bauchu E, Leroux D, Talmant P, Mozziconacci MJ, Mugneret F, Struski S, Raynaud S, Andrieux J, Barin C, Jotterand M, Mossafa H, Ramond S, Terré C, Lippert E, Berger F, Felman P, Merle-Béral H, Bernard OA, Davi F, Berger R, Nguyen-Khac F. The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. Leukemia. 2008 Nov;22(11):2123-7.

Maloum K, Settegrana C, Chapiro E, Cazin B, Leprêtre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F, Merle-Béral H. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Ann Hematol. 2009 Dec;88(12):1215-21..

Barbier S, Chatre L, Bras M, Sancho P, Roué G, Virely C, Yuste VJ, Baudet S, Rubio M, Esquerda JE, Sarfati M, Merle-Béral H, Susin SA. Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton. Haematologica. 2009 Apr;94(4):507-17.

Merle-Béral H, Barbier S, Roué G, Bras M, Sarfati M, Susin SA. Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia. Leukemia. 2009 May;23(5):974-7.

Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 Apr 30;113:4163-70.

Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Fermand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27:120-6.

Le Garff-Tavernier M, Ticchioni M, Brissard M, Salmon C, Raynaud S, Davi F, Bernard A, Merle-Béral H, Ajchenbaum-Cymbalista F, Letestu R. National standardization of ZAP-70 determination by flow cytometry: the French experience. Cytometry B Clin Cytom. 2007 Mar;72(2):103-8. Brugat T, Gault N, Baccelli I, Maës J, Roborel de Climens A, Nguyen-Khac F, Davi F, Merle-Béral H, Gilson E, Goodhardt M, Delic J. Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia. 2010 Jan;24(1):246-51.

Chapiro E, Leporrier N, Radford-Weiss I, Bastard C, Mossafa H, Leroux D, Tigaud I, De Braekeleer M, Terré C, Brizard F, Callet-Bauchu E, Struski S, Veronese L, Fert-Ferrer S, Taviaux S, Lesty C, Davi F, Merle-Béral H, Bernard OA, Sutton L, Raynaud SD, Nguyen-Khac F. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res. 2010 Jan;34(1):63-8.

Garnier A, Robin M, Larosa F, Golmard JL, Le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhédin N. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica. 2010 Jun;95:950-5.

Marteau JB, Rigaud O, Brugat T, Gault N, Vallat L, Kruhoffer M, Orntoft TF, Nguyen-Khac F, Chevillard S, Merle-Beral H, Delic J. Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. BMC Med Genomics. 2010 Nov 10;3:53.

Letestu R, Lévy V, Eclache V, Baran-Marszak F, Vaur D, Naguib D, Schischmanoff O, Katsahian S, Nguyen-Khac F, Davi F, Merle-Béral H, Troussard X, Ajchenbaum-Cymbalista F. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010 Nov 25;116(22):4588-90.

Brugat T, Nguyen-Khac F, Grelier A, Merle-Béral H, Delic J. Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood. 2010 Jul 15;116(2):239-49.

Perrot A, Pionneau C, Nadaud S, Davi F, Leblond V, Jacob F, Merle-Béral H, Herbrecht R, Béné MC, Gribben JG, Bahram S, Vallat L. A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.Blood. 2011 Jul 28;118(4):e1-15.

Grassin-Delyle S, Buenestado A, Vallat L, Naline E, Marx S, Decocq J, Debré P, Bernard OA, Advenier C, Devillier P, Merle-Béral H. Expression and proliferative effect of hemokinin-1 in human B-cells.Peptides. 2011 May;32(5):1027-34.

Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S, Jacob F, Ysebaert L, Susin SA, Merle-Béral H. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J. 2011 Feb;1(2):e5.

Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, Gonzalez H, Chapiro E, Radford-Weiss I, Leporrier N, Maloum K, Nguyen-Khac F, Davi F, Lejeune J, Merle-Béral H, Leporrier M; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Groupe Français d'étude de la Leucémie Lymphoïde Chronique (GFLLC). Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011 Jun 9;117(23):6109-19.

Nguyen-Khac F, Chapiro E, Lesty C, Grelier A, Luquet I, Radford-Weiss I, Lefebvre C, Fert-Ferrer S, Callet-Bauchu E, Lippert E, Raggueneau V, Michaux L, Barin C, Collonge-Rame MA, Mugneret F, Eclache V, Taviaux S, Dastugue N, Richebourg S, Struski S, Talmant P, Baranger L, Gachard N, Gervais C, Quilichini B, Settegrana C, Maloum K, Davi F, Merle-Béral H. Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia. Am J Blood Res. 2011;1(1):13-21.

Brugat T, Nguyen-Khac F, Merle-Béral H, Delic J. Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL. Leuk Res. 2011 May;35(5):e37-40.

Billot K, Soeur J, Chereau F, Arrouss I, Merle-Béral H, Huang ME, Mazier D, Baud V, Rebollo A. Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood. 2011 Feb 10;117(6):1917-27.

Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL, Merle-Beral H, Vieillard V. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011 Jan;25(1):101-9.

Lepretre S, Jäger U, Janssens A, Leblond V, Nikitin E, Robak T, Wendtner CM. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. Leuk Lymphoma. 2012;53:820-9.

Leblond V. [Chronic lymphocytic leukemia in elderly patients]. Rev Med Interne. 2012 Dec;33 Suppl 2:A18-20

Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 1;119(22):5104-10.

Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Leblond V. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.Clin Cancer Res. 2012 Sep 15;18(18):5043-50.

Viala K, Stojkovic T, Doncker AV, Maisonobe T, Lenglet T, Bruneteau G, Musset L, Neil J, Léger JM, Leblond V. Heterogeneous spectrum of neuropathies in Waldenström's macroglobulinemia: a diagnostic strategy to optimize their management. J Peripher Nerv Syst. 2012 Mar;17(1):90-101.

Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6.

Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblond V. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom macroglobulinemia. Haematologica. 2012 Oct 12.

Perrot A, Pionneau C, Azar N, Baillou C, Lemoine FM, Leblond V, Merle-Béral H, Béné MC, Herbrecht R, Bahram S, Vallat L. Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. Blood Cancer J. 2012 Sep 7;2:e88

Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, Davis Z, van Gastel-Mol EJ, Tresoldi C, Chu CC, Cahill N, Giudicelli V, Tichy B, Pedersen LB, Foroni L, Bonello L, Janus A, Smedby K, Anagnostopoulos A, Merle-Beral H, Laoutaris N, Juliusson G, di Celle PF, Pospisilova S, Jurlander J, Geisler C, Tsaftaris A, Lefranc MP, Langerak AW, Oscier DG, Chiorazzi N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012 May 10;119(19):4467-75.

Tsakou E, Agathagelidis A, Boudjoghra M, Raff T, Dagklis A, Chatzouli M, Smilevska T, Bourikas G, Merle-Beral H, Manioudaki-Kavallieratou E, Anagnostopoulos A, Brüggemann M, Davi F, Stamatopoulos K, Belessi C. Partial versus productive immunoglobulin heavy locus rearrangements in chronic lymphocytic leukemia: implications for B-cell receptor stereotypy. Mol Med. 2012 Feb 10;18:138-45.

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7

Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan;160:171-6

Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia. 2013 Feb 6. doi: 10.1038/leu.2013.36. Epub ahead of print.

PUBLICATIONS 2000- 2006

Binet JL

Emerging therapies and future directions in CLL--monoclonal antibodies, vaccines and gene therapy

Hematol Cell Ther. Jun;42(1):49-51 (2000)

 

Dighiero G, Binet JL

When and how to treat chronic lymphocytic leukemia

N Engl J Med. Dec 14;343(24):1799-801 (2000)

 

Leotard S, Chastang C, Travade P, Jaudon MC, Tournilhac O, Baudet S, et al

Prognostic relevance of a scoring system based on clinical and biological parameters in early chronic lymphocytic leukemia

Hematol J.;1(5):301-6 (2000)

 

Maloum K, Davi F, Merle-Beral H, Pritsch O, Magnac C, Vuillier F, et al

Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia

Blood. Jul 1;96(1):377-9 (2000)

 

Masdehors P, Merle-Béral H, Magdelenat H, Delic J.

Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytic apoptotic death activation.

Leukemia and Lymphoma, 2000, 38: 499-504.

 

Blaise R, Masdehors P, Lauge A, Stoppa-Lyonnet D, Alapetite C, Merle-Beral H, et al

Chromosomal DNA and p53 stability, ubiquitin system and apoptosis in B-CLL lymphocytes

Leuk Lymphoma. Nov-Dec;42(6):1173-80 (2001)

 

Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, et al

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

J Clin Oncol. Nov 15;19(22):4252-8 (2001)

 

Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, et al

Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease

Blood. Nov 1;98(9):2640-4 (2001)

 

Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

Blood. Oct 15;98(8):2319-25 (2001)

 

Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S

Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis

J Clin Epidemiol. Jul;54(7):747-54 (2001)

 

Levy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F, et al

Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis

Leukemia. Sep;15(9):1466-70 (2001)

 

Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B

Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia

Leuk Res. Nov;25(11):967-80 (2001)

 

Vuillier F, Maloum K, Thomas EK, Jouanne C, Dighiero G, Scott-Algara D

Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia

Br J Haematol. Dec;115(4):831-44 (2001)

 

Dighiero G

Chronic lymphoid leukemia: a single disease or 2 distinct diseases?

Bull Acad Natl Med. 186(7):1251-66; discussion 66-8 (2002)

 

Dighiero G

Is chronic lymphocytic leukemia one disease?

Haematologica. Dec;87(12):1233-5 (2002)

 

Gonzalez H, Maloum K, Remy F, Merle-Beral H, Lesty C

Cleaved lymphocytes in chronic lymphocytic leukemia: a detailed retrospective analysis of diagnostic features

Leuk Lymphoma. Mar;43(3):555-64 (2002)

 

Johnson SA, Oscier DG, Leblond V

Waldenstrom's macroglobulinaemia

Blood Rev. Sep;16(3):175-84 (2002)

 

Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, et al

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

J Clin Oncol. Jan 1;20(1):205-13 (2002)

 

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Blood. May 15;99(10):3554-61 (2002)

 

Maloum K, Sutton L, Baudet S, Laurent C, Bonnemye P, Magnac C, et al

Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia

Br J Haematol. Dec;119(4):970-5 (2002)

 

Oppezzo P, Magnac C, Bianchi S, Vuillier F, Tiscornia A, Dumas G, et al

Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells

Leukemia. Dec;16(12):2438-46 (2002)

 

Payelle-Brogard B, Magnac C, Alcover A, Roux P, Dighiero G

Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia

Br J Haematol. Sep;118(4):976-85 (2002)

 

Samson T, Mossafa H, Lusina D, Fagot T, Souleau B, de Revel T, et al

Dicentric chromosome 3 associated with binucleated lymphocytes in atypical B-cell chronic lymphoproliferative disorder

Leuk Lymphoma. Sep;43(9):1749-54 (2002)

 

Theodorou I, Abel L, Mauro F, Duprey B, Magnac C, Payelle-Brogard B, et al

High occurence of DRB1 11 in chronic lymphocytic leukaemia families

Br J Haematol. Dec;119(3):713-5 (2002)

 

Blaise R, Alapetite C, Masdehors P, Merle-Beral H, Roulin C, Delic J, Sabatier L.

High levels of chromosome aberrations correlate with impaired in vitro radiation-induced apoptosis and DNA repair in human B-chronic lymphocytic leukaemia cells.

Int J Radiat Biol. 2002 Aug;78(8):671-9.

 

Dighiero G

Unsolved issues in CLL biology and management

Leukemia. Dec;17(12):2385-91 (2003)

 

Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Semin Oncol. Apr;30(2):116-20 (2003)

 

Leblond V, Choquet S

Fludarabine in Waldenstrom's macroglobulinemia

Semin Oncol. Apr;30(2):239-42 (2003)

 

Magnac C, Porcher R, Davi F, Nataf J, Payelle-Brogard B, Tang RP, et al

Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL

Leukemia. Jan;17(1):133-7 (2003)

 

Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, et al

Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation

Blood. May 15;101(10):4029-32 (2003)

 

Payelle-Brogard B, Magnac C, Oppezzo P, Dumas G, Dighiero G, Vuillier F

Retention and defective assembly of the B-cell receptor in the endoplasmic reticulum of chronic lymphocytic leukaemia B cells cannot be reverted upon CD40 ligand stimulation

Leukemia. Jun;17(6):1196-9 (2003)

 

Roue G, Krieger S, Florent M, Roussel M, Duquesne F, Troussard X, et al

Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing B-malignancies: relevance for the pathogenesis

Leukemia. Mar;17(3):652-5 (2003)

 

Roussel M, Roue G, Sola B, Mossafa H, Troussard X

Dysfunction of the Fas apoptotic signaling pathway in persistent polyclonal B-cell lymphocytosis

Haematologica. Feb;88(2):239-40 (2003)

 

Sanhes L, Tang R, Delmer A, DeCaprio JA, Ajchenbaum-Cymbalista F

Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases

Leukemia. Jun;17(6):1104-11 (2003)

 

Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al

Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells

Blood. Jan 1;101(1):265-9 (2003)

 

Stalnikiewicz L, Carrotte-Lefebvre I, Detourmignies L, Rose C, Cazin B, Leblond V, et al Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients

Semin Oncol. Apr;30(2):216-9 (2003)

 

Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, et al

Transplantation in Waldenstrom's macroglobulinemia--the French experience

Semin Oncol. Apr;30(2):291-6 (2003)

 

Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, et al

Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia

J Clin Oncol. Nov 1;21(21):3928-32 (2003)

 

Vuillier F, Dighiero G

Cell therapy by dendritic cells in chronic lymphoid leukemia: state of the art

Bull Cancer. Aug-Sep;90(8-9):744-50 (2003)

 

Vuillier F, Dighiero G

Monocyte-derived dendritic cells in chronic lymphocytic leukemia

Leuk Lymphoma. Aug;44(8):1267-73 (2003)

 

Vuillier F, Maloum K, Thomas EK, Magnac C, Dumas G, Payelle-Brogard B, et al

Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia

Br J Haematol. Jan;120(2):243-50 (2003)

 

Guipaud O, Deriano L, Salin H, Vallat L, Sabatier L, Merle-Béral H, Delic J. B-cell chronic lymphocytic leukaemia : a polymorphic family unified by genomic features.

Lancet Oncology. 2003;4 :505-514.

 

Binet JL

Fludarabine in chronic lymphocytic leukemia and other hematological malignancies: progress in treatment

Fludarabine supplement

Hematol J.;5 Suppl 1:S1 (2004)

 

Binet JL

Patient management decisions in chronic lymphocytic leukemia: an introduction and an editorial

Semin Hematol. Jul;41(3):191 (2004)

 

Dighiero G

Perspectives in chronic lymphocytic leukemia biology and management

Hematol Oncol Clin North Am. Aug;18(4):927-43, x (2004)

 

Leblond V, Tournilhac O, Morel P

Waldenstrom's macroglobulinemia: prognostic factors and recent therapeutic advances

Clin Exp Med. Apr;3(4):187-98 (2004)

 

Leporrier M

Chronic lymphocytic leukemia

Rev Prat. Feb 29;54(4):359-67 (2004)

 

Leporrier M

Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia Hematol J.;5 Suppl 1:S10-9 (2004)

 

Tchirkov A, Chaleteix C, Magnac C, Vasconcelos Y, Davi F, Michel A, et al

hTERT expression and prognosis in B-chronic lymphocytic leukemia

Ann Oncol. Oct;15(10):1476-80 (2004)

 

Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia

Blood. Jan 1;103(1):363-5 (2004)

 

Pérez-Andrés M, Santiago M, Almeida J, Mateo G, Porwit-MacDonald A, Bjorklund E, Valet G, Kraan J, Gratama JW, D’Hautcourt JL, Merle-Béral H, Lima M, Montalban MA, San Miguel JF, Orfao A; for the European Working Group on Clinical Cell Analysis (EWGCCA) and the Spanish Network on Multiple Myeloma.

Immunophenotypic approach to the identification and charaterization of clonal plasma cells from patients with monoclonal gammopathies.

J Biol Regul and Homeost Agents 2004; 18:392-398.

 

Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff –Tavernier M, Ong J, Berger R, V Leblond, Merle-Béral H.

Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.

Cancer Genetics and Cytogenetics. 2005, (159) : 74-78.

 

Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G, et al

Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway

Blood. Jun 15;105(12):4776-83 (2005)

 

Leucémie Lymphoïde Chronique.

Merle-Beral H.

Hématologie Clinique et Biologique (2ème édition). Editions Arnette: 2005, 285-292.

 

Dighiero G

CLL Biology and Prognosis

Hematology (Am Soc Hematol Educ Program).:278-84 (2005)

 

Deriano L, Guipaud O, Merle-Béral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, Sabatier L, Delic J

Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathways

Blood. Jun 15;105(12):4776-83 (2005)

 

Dimopoulos MA, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R

How we treat Waldenstrom's macroglobulinemia

Haematologica. Jan;90(1):117-25 (2005)

 

Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, et al

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene

Blood. Feb 15;105(4):1678-85 (2005)

 

Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, et al

Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders

Clin Lymphoma. Mar;5(4):294-7 (2005)

 

Leblond V

Waldenstrom's macroglobulinemia and bortezomib

Haematologica. Dec;90(12):1589A (2005)

 

Levy V, Morel P, Porcher R, Chevret S, Wattel E, Leblond V

Advanced Waldenstrom's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis

Haematologica. Feb;90(2):279-81 (2005)

 

Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, et al

Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations

Blood. Jan 15;105(2):767-74 (2005)

 

Oppezzo P, Dighiero G

What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?

Curr Top Microbiol Immunol.;294:71-89 (2005)

 

Oppezzo P, Dumas G, Lalanne AI, Payelle-Brogard B, Magnac C, Pritsch O, et al

Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells

Blood. Mar 15;105(6):2495-503 (2005)

 

Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, et al

The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia

Blood. Jul 15;106(2):650-7 (2005)

 

Tamburini J, Levy V, Chaleteix C, Fermand JP, Delmer A, Stalniewicz L, et al

Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients

Leukemia. Oct;19(10):1831-4 (2005)

 

Treon SP, Morel P, Leblond V, Fermand JP

Report of the Third International Workshop on Waldenstrom's macroglobulinemia

Clin Lymphoma. Mar;5(4):215-6 (2005)

 

Vasconcelos Y, De Vos J, Vallat L, Reme T, Lalanne AI, Wanherdrick K, et al

Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes

Leukemia. Nov;19(11):2002-5 (2005)

 

Vuillier F, Dumas G, Magnac C, Prevost MC, Lalanne AI, Oppezzo P, et al

Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains

Blood. Apr 1;105(7):2933-40 (2005)

 

Opezzo P, Dighiero G

What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis ?

Curr Top Microbiol Immunol. 294:71-89 (2005)

 

Dighiero G

CLL biology and prognosis

Hematology (Am Soc Hematol Educ Program). 278-84 (2005)

 

Leblond V, Tournilhac O.

La maladie de Waldenström ou Macroglobulinémie. Hématologie, 2005; 11: 408-416

 

Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al

Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia

Blood. Feb 1;107(3):859-61 (2006)

 

Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V et al

Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia

Blood. Jan 12 (2006) (Epub eahead of print)

 

Payelle-Brogard B, Dumas G, Magnac C, Lalanne AI, Dighiero G, Vuillier F

Abnormal levels of the alpha chain of the CD22 adhesion molecule may account for low CD22 surface expression in chronic lymphocytic leukaemia

Leukemia. Feb 23 (2006)

 

Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P, Dalloul A.

High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia.

Leukemia. 2006 Mar; 20(3):498-504

 

Leblond V, Tournilhac O, Morel P.

Maladie de Waldenström ou macroglobulinémie

EMC 2006

Belessi CJ, Davi FB, Stamatopoulos KE, Degano M, Andreou TM, Moreno C, Merle-Béral H, Crespo M, Laoutaris NP, Montserrat E, Caligaris-Cappio F, Anagnostopoulos AZ, Ghia P. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. Eur J Immunol. 2006 Jul;36(7):1963-74.

Maloum K, Charlotte F, Divine M, Cazin B, Lesty C, Merle-Béral H; French Cooperative Group on CLL. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia. Haematologica. 2006 Jun;91(6):860-1.

Bouley J, Deriano L, Delic J, Merle-Béral H. New molecular markers in resistant B-CLL. Leuk Lymphoma. 2006 May;47(5):791-801. Review.

Deriano L, Merle-Béral H, Guipaud O, Sabatier L, Delic J. Mutagenicity of non-homologous end joining DNA repair in a resistant subset of human chronic lymphocytic leukaemia B cells. Br J Haematol. 2006 Jun;133(5):520-5.

Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P, Dalloul A. High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia. Leukemia. 2006 Mar;20(3):498-504

Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Bladé J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3

PUBLICATIONS 1991-2000

Huret JL, Brizard A, Dreyfus B, Tanzer J.

Homozygote breakpoint in 13q14 in a case of chronic lymphocytic leukemia.

Cancer Genet Cytogenet. 1991 Dec;57(2):231-2 

 

Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL

B-cell chronic lymphocytic leukemia: present status and future directions

French Cooperative Group on CLL.

Blood. Oct 15;78(8):1901-14 (1991)

 

Merle-Beral H, Legac E, Chastang C, Michel A, Debre P, Binet JL

CD1c is not a feature of mixed-cell type but of a typical form of chronic lymphocytic leukaemia

Eur J Haematol. Feb;48(2):120 (1992)

 

Montserrat E, Binet JL, Catovsky D, Dighiero G, Gale RP, Rai KR, et al

5th International Workshop on Chronic Lymphocytic Leukemia

Leuk Res. Jun-Jul;16(6-7):717-20 (1992)

 

Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S, et al

Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangement

Leuk Lymphoma. Jun;7(3):195-204 (1992)

 

Binet JL

When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)?

The French Cooperative Group on C.L.L

Hematol Oncol. 11 Suppl 1:38 (1993)

 

Binet JL

Fludarabine phosphate in chronic lymphoproliferative diseases

The French Group on CLL

Nouv Rev Fr Hematol. Feb;35(1):5-7 (1993)

 

Binet JL

Treatment of chronic lymphocytic leukaemia

French Co-operative Group on CLL

Baillieres Clin Haematol. Dec;6(4):867-78 (1993)

 

Dighiero G

Biology of the neoplastic lymphocyte in B-CLL

Baillieres Clin Haematol. Dec;6(4):807-20 (1993)

 

Brizard A, Brizard F, Lessard M, Dreyfus B, Guilhot F, Tanzer J.

Improvement of cytogenetic results in B-cell chronic lymphocytic leukemia using immuno-purified leukemic cells.

 Nouv Rev Fr Hematol. 1993 Feb;35(1):103-5

 

Michel F, Merle-Beral H, Legac E, Michel A, Debre P, Bismuth G.

Defective calcium response in B-chronic lymphocytic leukemia cells : alteration of early protein tyrosine phosphorylation and of the mechanism responsible for cell calcium influx. J. Immunol.: 1993, 150, 3624-3633.

 

Dighiero G

Potential immunological action of purine nucleoside analogues

Drugs. 47 Suppl 6:57-62 (1994)

 

Brizard A, Brizard F, Dreyfus B, Morel F, Lecron JC, Tanzer J, Preud'homme JL.

Chromosomal analysis of purified B-chronic lymphocytic leukemia lymphocyte cultures: comparison with whole blood cultures and in situ hybridization

 Leuk Lymphoma.1993 Nov;11(5-6):379-85

 

Dighiero G

Autoantibody activity and V gene usage by B-cell malignancies

Adv Exp Med Biol. 347:125-33 (1994)

 

Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K

Recent progress in chronic lymphocytic leukemia

International Workshop on chronic Lymphocytic Leukemia

Leukemia. Sep;8(9):1610-4 (1994)

 

Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, et al

Chronic lymphoproliferative disorders

Rev Invest Clin. Apr;Suppl:52-8 (1994)

 

Schroeder HW, Jr., Dighiero G

The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire

Immunol Today. Jun;15(6):288-94 (1994)

 

Brizard A, Morel F, Lecron JC, Dreyfus B, Brizard F, Barra A, Preud'homme JL.

Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23.

Leuk Lymphoma. 1994 Jul;14(3-4):311-8

 

Binet JL, Mentz F, Baudet S, Ouaaz F, Merle-Beral H

In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications

Bull Acad Natl Med. Oct;179(7):1379-91; discussion 91-2 (1995)

 

Binet JL, Mentz F, Leblond V, Merle-Beral H

Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia

Leukemia. Dec;9(12):2159-61 (1995)

 

Maloum K, Davi F, Magnac C, Pritsch O, McIntyre E, Valensi F, et al

Analysis of VH gene expression in CD5+ and CD5- B-cell chronic lymphocytic leukemia

Blood. Nov 15;86(10):3883-90 (1995)

 

Mentz F, Merle-Beral H, Ouaaz F, Binet J

Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides

Br J Haematol. Aug;90(4):957-9 (1995)

 

Salomon-Nguyen F, Valensi F, Merle-Beral H, Flandrin G.

A scoring system for the classification of CD5-B CLL versus CD5+B CLL and B PLL.

Leukemia and Lymphoma: 1995, 16, 445-450.

 

Mentz F, Merle-Beral H, Ouaaz F, Dmossalyi M, Binet J.L.

Theophylline, a new inducer of apoptosis in B-CLL. Role of cyclic nucleotides.

British J of Haematol.: 1995, 90, 957-959.

 

Binet JL, Plunkett W, Robertson B, Merle-Beral H, Mentz F, Hoffbrand AV, et al

What does apoptosis mean in CLL?

 

Leuk Lymphoma. Oct;22 Suppl 2:47-52 (1996)

Dighiero G

Adverse and beneficial immunological effects of purine nucleoside analogues

Hematol Cell Ther. Dec;38 Suppl 2:S75-81 (1996)

 

Dighiero G, Binet JL

Chronic lymphocytic leukemia

Hematol Cell Ther. Dec;38 Suppl 2:S41-61 (1996)

 

 

Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F, Silberstein LE, et al

What is the CLL B-lymphocyte?

Leuk Lymphoma. Oct;22 Suppl 2:13-39 (1996)

 

Mentz F, Mossalayi MD, Ouaaz F, Baudet S, Issaly F, Ktorza S, et al

Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells

Blood. Sep 15;88(6):2172-82 (1996)

 

Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al

Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia

Blood. Dec 1;88(11):4259-64 (1996)

 

Beaume A, Brizard A, Dreyfus B, Preud'homme JL.

High incidence of serum monoclonal IgS detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia.

Blood.1994 Aug 15;84(4):1216-9

 

Brizard F, Dreyfus B, Guilhot F, Tanzer J, Brizard A.

11q13 rearrangement in B cell chronic lymphocytic leukemia.

 Leuk Lymphoma.1997 May;25(5-6):539-43

 

Dighiero G

Chronic lymphocytic leukemia treatment

Hematol Cell Ther. Nov;39 Suppl 1:S31-40 (1997)

 

Maloum K, Pritsch O, Dighiero G

Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement Hematol Cell Ther. Jun;39(3):119-24 (1997)

 

Maloum K, Pritsch O, Magnac C, Davi F, Binet JL, Merle-Beral H, et al

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies Leuk Lymphoma. Feb;24(5-6):437-48 (1997)

 

Pritsch O, Maloum K, Magnac C, Davi F, Binet JL, Merle-Beral H, et al

What do chronic B cell malignancies teach us about B cell subsets?

Chem Immunol.;67:85-101 (1997)

 

Astier A, Merle-Beral H, De La Salle H, Moncuit J, Cazenave J.P, Herman Fridman W, Hanau D, Teillaud J.L.

Soluble Fcg Receptor, Fcg RIIa2, exists under two forms in human serum and is increased in patients with stage C of B Chronic Lymphocytic Leukemia.

Leukemia and Lymphoma: 1997, 26, 317-326.

 

Semichon M, Merle-Beral H, Lang V and Bismuth G.

Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells.

Leukemia: 1997, 11, 1921-1928.

 

Dighiero G

Autoimmunity and B-cell malignancies

Hematol Cell Ther. Feb;40(1):1-9 (1998)

 

Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al

Chlorambucil in indolent chronic lymphocytic leukemia

French Cooperative Group on Chronic Lymphocytic Leukemia

N Engl J Med. May 21;338(21):1506-14 (1998)

 

Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, et al

Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases.

Groupe Cooperatif Macroglobulinemie

J Clin Oncol. Jun;16(6):2060-4 (1998)

 

Maloum K, Magnac C, Azgui Z, Cau C, Charlotte F, Binet JL, et al

VH gene expression in hairy cell leukaemia

Br J Haematol. Apr;101(1):171-8 (1998)

 

Mentz F, Baudet S, Blanc C, Issaly F, Binet JL, Merle-Beral H

Simple, fast method of detection apoptosis in lymphoid cells

Cytometry. Jun 1;32(2):95-101 (1998)

 

Pritsch O, Maloum K, Dighiero G

Basic biology of autoimmune phenomena in chronic lymphocytic leukemia

Semin Oncol. Feb;25(1):34-41 (1998)

 

Sutton L, Maloum K, Gonzalez H, Zouabi H, Azar N, Boccaccio C, et al

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

Leukemia. Nov;12(11):1699-707 (1998)

 

Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F

Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia

Blood. Jun 15;91(12):4694-700 (1998)

 

Zhao H, Dugas N, Mathiot C, Delmer A, Dugas B, Sigaux F, et al

B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity

Blood. Aug 1;92(3):1031-43 (1998)

 

Binet JL

Prognostic factors in chronic lymphocytic leukaemia

Haematologica. Jun;84 Suppl EHA-4:96-7 (1999)

 

Cheze S, Leporrier M

Chronic lymphoid leukemia. Diagnosis, course, prognosis, principles of treatment

Rev Prat. Mar 1;49(5):539-46 (1999)

 

Magnac C, Sutton L, Cazin B, Laurent C, Binet JL, Merle-Beral H, et al

Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL)

Hematol Cell Ther. Feb;41(1):13-8 (1999)

 

Lacombe C, Gombert J, Dreyfus B, Brizard A, Preud'homme JL.

Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia.

Clin Immunol. 1999 Jan;90(1):128-32

 

Payelle-Brogard B, Magnac C, Mauro FR, Mandelli F, Dighiero G

Analysis of the B-cell receptor B29 (CD79b) gene in familial chronic lymphocytic leukemia Blood. Nov 15;94(10):3516-22 (1999)

 

Pritsch O, Troussard X, Magnac C, Mauro FR, Davi F, Payelle-Brogard B, et al

VH gene usage by family members affected with chronic lymphocytic leukaemia

Br J Haematol. Dec;107(3):616-24 (1999)

 

Sola B, Salaun V, Ballet JJ, Troussard X

Transcriptional and post-transcriptional mechanisms induce cyclin-D1 over-expression in B-chronic lymphoproliferative disorders

Int J Cancer. Oct 8;83(2):230-4 (1999)

 

Mentz F, Merle-Beral H, Dalloul Ali. H.

Theophylline-induced B-CLL apoptosis is partly dependant on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production.

Leukemia. 1999, 13, N°1, 78-84

PUBLICATIONS 1981-1990

Dighiéro G, Bodega E, and Binet JL

Differentiation ability of the CLL lymphocyte : an immature lymphocyte or an abnormal leukemic cell ?

Blood Cells. 7, 331-339 (1981)

 

A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis

Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, and Gremy G

Reprinted from Cancer. vol. 48, n°1, July 1 (1981)

 

Binet JL.

New data on the prognosis of chronic lymphoid leukemia ; anatomo-clinical classification Acquis Med Recent. 198:191-200 (1981)

 

Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

Cancer. Jul 1;48(1):198-206 (1981)

 

Dighiero G, Bodega E, Binet JL

Differentiation ability of the CLL lymphocyte: an immature lymphocyte or an abnormal leukemic cell ?

Blood Cells. 7(2):331-9 (1981)

 

Raphael M, Ployart F, Diebold J, Sultan C, Chomette G, Brousse N, et al

Review, by a group of pathologists, of bone marrow biopsies in chronic lymphocytic leukemia. Apropos of 109 cases with a statistical analysis and anatomo-clinical correlation]

Ann Pathol. 3(2):119-26 (1983)

 

Praz F, Karsenty G, Binet JL, Lesavre

Complement alternative pathway activation by chronic lymphocytic leukemia cells: its role in their hepatosplenic localization

Blood.  Feb;63(2):463-7 (1984)

 

Chastang C, Travade P, and Auquier A

Critical discussion of the assessment of a three-stage prognostic classification for chronic lymphocytic leukaemia

Statistics in Medicine. vol. 4, 287-293 (1985)

 

Lebrun E, Ajchenbaum F, Troussard X, Galateau F, Leporrier M, Lacombe C, et al

Chronic lymphocytic leukemia, erythroblastopenia, thymolipoma

Nouv Rev Fr Hematol. 27(1):29-37 (1985)

 

Binet JL, Travade P, Chastang C, Dighiero G, Merle-Beral H, Raphael M

Biological aspects of chronic lymphoid leukaemia

C R Seances Soc Biol Fil. 180(5):503-11 (1986)

 

Chastang C, Travade P, Benichou J, Dighiero G, Binet JL

Patient accrual and interim statistical analysis in long-term randomized clinical trials: the French chronic lymphocytic leukemia CLL 80 protocol as a case study

Stat Med. Sep-Oct;5(5):465-73 (1986)

 

Travade P, Dusart JD, Cavaroc M, Beytout J, Rey M

Severe infections associated with chronic lymphoid leukemia. 159 infectious episodes in 60 patients

Presse Med. Oct 11;15(34):1715-8. French (1986)

 

Dighiero G, Binet JL

Does the CLL B lymphocyte correspond to expansion of an immature B clone or to expansion of a distinct subpopulation of B cells?

Blood Cells. 12(2):385-97 (1987)

 

Travade P, Chastang C, Dighiero G, Binet JL

New trends in CLL treatment

 Blood

 

Synergistic effect of recombinant IL2 and Interferon on the proliferation of human monoclonal lymphocytes

Karray S,  Vazquez A, Merle-Beral H, Olive F, Debré P , Galanaud P

J Immunol 11,3824-3828 ( 1987 )

 

 Functional heterogeneity of B-CLL lymphocytes:dissociated responsiveness to growth factors nd distinct requirements for a first activation signal

Karray S, Merle-Beral H, Vazquez A, Gerard JP, Galanaud P

Blood, 70, 1105-1110 (1987)

 

French Cooperative Group on Chronic Lymphocytic Leukemia

Comparison of the (A, B, C) staging and the Rai’s staging from a large prospective series (935 patients)

Nouv. Rev. Fr. Hématol. 30, 363-367 (1988)

PUBLICATIONS 1977-1980

Binet JL, Dighiero G, Leporrier M. Follezou JY, Charron D and Debré P

Surveillance of chronic lymphocytic leukemia

Blood Cells. 3, 651-653 (1977)

 

Binet JL, Leporier M, Dighiero G, Charron D, D'Athis P, Vaugier G, et al

A clinical staging system for chronic lymphocytic leukemia: prognostic significance.

Cancer. 40(2), 855-64 (1977)

 

Charron D, Dighiero G, Raphael M, Binet JL

Bone-marrow patterns and clinical staging in chronic lymphocyte leukaemia

Lancet. Oct 15, 2(8042):819 (1977)

 

Dighiero G, Follezou JY, Binet JL

Surface immunoglobulins in lymphocytic leukemias

Blood. Jul 50(1):179 (1977)

 

Dighiero G, Follezou JY, Roisin JP, Charron D, Bouvet E, Ternyck T, et al

The quantification of surface immunoglobulins in lymphoproliferative syndromes

Nouv Rev Fr Hematol Blood Cells. 18(1):180-1 (1977)

 

Dighiero G, Vaugier G, Charron D, d'Athis P, Binet JL

Variations in lymphocyte counts four hours after administration of hydrocortisone in patients with chronic lymphocytic leukaemia

Blood. May 49(5):719-28 (1977)

 

Binet JL, Dighiero G, Vaugier G , Charron D, Leporrier M, Debré P Merle-Beral H, Raphael M, D’Athis P

Contribution of automation in the classification of chronic lymphocytic leukemia

Excerpta Medica , 415, 679-82( 1978 )

 

Dighiero G

Lymphocyte membrane markers in chronic lymphoid leukemia

Nouv Rev Fr Hematol. Suppl:VII-IX (1979)

 

Dighiero G, Lesty C, Couty MC, et Binet JL

Valeur pronostique de l’étude des volumes lymphocytaires dans la leucémie lymphoïde chronique

Nouv. Rev. Fr. Hématol. 22, 383-390 (1980)

 

Dighiero G, Bodega E, Mayzner R, Binet JL

Individual cell-by-cell quantitation of lymphocyte surface membrane Ig in normal and CLL lymphocyte and during ontogeny of mouse B lymphocytes by immunoperoxidase assay

Blood. Jan 55(1):93-100 (1980)

 

Dighiero G, Bodega E, Mayzner R, Binet JL

Two new applications of the immunoperoxidase method: cell-by-cell quantitation of surface immunoglobulins and automated recognition of B-lymphocytes

Blood Cells. 6(3):371-9 (1980)

 

Dighiero G, Lesty C, Couty MC, Binet JL

Prognostic value of the study of lymphocytic volumes in chronic lymphocytic leukemia (author's transl)

Nouv Rev Fr Hematol. 22(4):383-90 (1980)